This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
DigitalHealth Technologies ( DHTs ) have revolutionized the landscape of clinical trials, particularly in neurology research, by enabling the collection of real-world data outside traditional clinical settings.
Our mission is to accelerate the commercialization of breakthrough innovations like the AUTAC platform for health impact, and we welcome Automera and ALSP to Singapore’s growing lifesciences translational community.”
–(BUSINESS WIRE)–AstraZeneca today launches Evinova, set to be a leading provider of digitalhealth solutions to better meet the needs of healthcare professionals, regulators and patients. .–(BUSINESS in 2060.
In this scenario, a patient can digitally determine who should have access to the medical record (and which portion), which person(s) or entities saw or modified the record (and what portion) and when. Herding a patient’s data from many sources into a single record has always been a lofty goal of digitalhealth.
With ResponderID, we sought to disrupt the historical linear progression of drug discovery and development, rather aiming to close the loop between drugdevelopment, patient care and new drug discovery,” said Rafael Rosengarten, Ph.D., co-founder and CEO of Genialis. “We
Deerfield invests across the lifescience, medical device, diagnostic, digitalhealth, and health service industries at every stage of evolution. COTA, Inc. , In conjunction, COTA announced it has raised additional capital from existing investors.
Koneksa’s digital biomarker solutions include an industry-leading platform that gives research sponsors and clinical sites the ability to seamlessly aggregate data in real-time from devices, ePROs, patient diaries, and clinical assessments to provide the full picture of an individual’s health.
The striking increase suggests rising industry confidence in the use of digital technology in clinical trials and a strategy shift from tentative, careful adoption to wide scale implementation of eCOA solutions across therapeutic areas, portfolios, regions, and even across the enterprise. 5 at 9:55am. 5000 in 2024.
Founded in 2018 and supported from the outset by LallianSe, the lifesciences integrator, BrainTale has developed and commercializes an accessible, reliable and clinically validated brain measurement digital platform solution for drugdevelopers and physicians – neurologists, neuroradiologists and intensivists.
Healthcare stakeholders such as health systems, pharmaceutical companies, biotech and lifesciences firms, and insurance companies serve patients as end users. Market forces drove acceleration in digitalhealth, specifically telemedicine, which were sorely needed for several years.
QuantHealth bridges these gaps by simulating trials at scale, to expedite, derisk, and optimize drugdevelopment. This decline is happening at a time when the need for efficient drugdevelopment has never been greater. This happens because there are major gaps in the research needed to support clinical trials.
AI-powered* platform takes eCOA off the critical path to study startup for lifesciences industry PALO ALTO, Calif.–(BUSINESS Its digital clinical trials platform enhances speed, scale, and patient access in clinical research, accelerating medicines for thousands of conditions without treatment or cure.
The new seed funding activity will therefore pave the way for the next generation of treatments and digitalhealth, providing healthcare professionals with better tools to improve experiences and outcomes for patients. Since 2017 Debiopharm has invested in 15 AI and digitalhealth companies, typically leading the investment rounds.
Their expertise in company building, capital formation, and drugdevelopment will be a tremendous resource to Avilar as the innovation leader in the new field of extracellular protein degradation.” For more information, please visit www.avilar-tx.com and follow us on Twitter @Avilar_Tx and on LinkedIn.
Aviceda Glycotech looks forward to this collaboration aimed at developing the next generation of cancer checkpoint immune therapeutics in Belfast. “It Its mission is to improve patient outcomes, train the next generation of scientists and clinicians, and enhance the competitiveness of the UK lifesciences sector.
This comes after Francisco Partners, a private equity firm, acquired the health analytics assets of IBM Watson Health in 2022 and rebranded the division as Merative. Merative's product portfolio will focus on six key areas: Health Insights: Providing actionable insights to improve healthcare delivery and decision-making.
Cornerstone’s founders incubated the company in partnership with Initiate Studios, a new venture studio that co-creates companies at the intersection of healthcare, lifesciences and technology. Poor quality data leads to drugdevelopment being delayed, patients being misdiagnosed and inaccurate scientific conclusions.
Chris McSpiritt, Head of LifeSciences at Domino Data Lab Next year will see AI-enhanced imaging technologies significantly improve diagnostic accuracy in radiology and pathology, empowering clinicians to make quicker and more reliable decisions at the point of care. Today, it’s largely restricted to genomics and oncology.
These individuals have personally built leading technology platforms supercharging drugdevelopment globally. Their buy-in shows that our platform is differentiated and poised to unlock truly novel therapies for currently underserved patient populations through efficient, simulation-guided development. Dr. Bernd Seizinger, M.D.,
The WHO and the India G20 presidency emphasised its importance by launching ‘The Global Initiative of DigitalHealth’ (GIDH) in August, proclaiming: “Digitalhealth is a proven accelerator to advance health outcomes and achieve Universal Health Coverage and health-related Sustainable Development Goals.”
With access to these collective resources and by capitalizing on existing biosamples as well as clinical data, including that from digitalhealth technology, researchers will focus on identifying and validating biomarkers and therapeutic targets specific to ALS.
The seed round was co-led by Wellington Partners and Forbion and includes non-dilutive financing from BMBF GO-Bio, a prestigious German government initiative aimed at supporting the most innovative startups in the lifesciences. Forbion invests in lifesciences companies that are active in the (bio) pharmaceutical space.
We organize all of the trending information in your field so you don't have to. Join 48,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content